Theriva Biologics, Inc. (TOVX) shares rose 24.03 percent to $0.2306, gaining $0.0447 on Monday, after the company reported positive regulatory feedback from the U.S. FDA on its lead cancer therapy program.
The stock is currently trading at $0.2306 compared with its previous close of $0.1859. Shares opened at $0.1856 and traded between $0.2375 and $0.2801 during the session on the Nasdaq. Trading volume reached about 157.58 million shares, above the average volume of about 10.27 million shares.
The company said the FDA generally agreed with the proposed Phase 3 trial design for VCN-01 in combination with standard chemotherapy for metastatic pancreatic adenocarcinoma, including the primary endpoint of overall survival and the use of an adaptive design. The update follows successful Phase 2 VIRAGE trial results, where VCN-01 improved overall survival, progression free survival and duration of response compared with chemotherapy alone.
The stock has traded in a 52-week range of $0.16 to $1.50.
For comments and feedback contact: editorial@rttnews.com
Business News
May 08, 2026 15:50 ET Manufacturing and services sector survey results and labor market data from main economies were the highlight on the economics news front this week. Factory orders and jobs report dominated the news flow in the U.S. Similarly, industrial production data from German garnered attention in Europe. In Asia, purchasing managers’ survey results from China and the central bank decision from Australia were in focus.